NRx Pharmaceuticals Statistics
Share Statistics
NRx Pharmaceuticals has 16.92M
shares outstanding. The number of shares has increased by 58.08%
in one year.
Shares Outstanding | 16.92M |
Shares Change (YoY) | 58.08% |
Shares Change (QoQ) | 39.87% |
Owned by Institutions (%) | 0.03% |
Shares Floating | n/a |
Failed to Deliver (FTD) Shares | 41,709 |
FTD / Avg. Volume | 20.06% |
Short Selling Information
The latest short interest is 1.24M, so 7.36% of the outstanding
shares have been sold short.
Short Interest | 1.24M |
Short % of Shares Out | 7.36% |
Short % of Float | 8.27% |
Short Ratio (days to cover) | 8.35 |
Valuation Ratios
The PE ratio is -0.92 and the forward
PE ratio is 1.34.
NRx Pharmaceuticals's PEG ratio is
0.02.
PE Ratio | -0.92 |
Forward PE | 1.34 |
PS Ratio | 0 |
Forward PS | 0 |
PB Ratio | -1 |
P/FCF Ratio | -2.18 |
PEG Ratio | 0.02 |
Financial Ratio History Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NRx Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15,
with a Debt / Equity ratio of -0.28.
Current Ratio | 0.15 |
Quick Ratio | 0.15 |
Debt / Equity | -0.28 |
Debt / EBITDA | -0.36 |
Debt / FCF | -0.62 |
Interest Coverage | -80.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | $-12,563,000 |
Employee Count | 2 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 0.49% in the
last 52 weeks. The beta is 1.41, so NRx Pharmaceuticals's
price volatility has been higher than the market average.
Beta | 1.41 |
52-Week Price Change | 0.49% |
50-Day Moving Average | 2.07 |
200-Day Moving Average | 2.01 |
Relative Strength Index (RSI) | 52.93 |
Average Volume (20 Days) | 207,888 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -18.5M |
Net Income | -25.13M |
EBITDA | -18.5M |
EBIT | -24.9M |
Earnings Per Share (EPS) | -2.39 |
Full Income Statement Balance Sheet
The company has 1.44M in cash and 6.58M in
debt, giving a net cash position of -5.13M.
Cash & Cash Equivalents | 1.44M |
Total Debt | 6.58M |
Net Cash | -5.13M |
Retained Earnings | -278.27M |
Total Assets | 3.65M |
Working Capital | -18.56M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -10.64M
and capital expenditures 0, giving a free cash flow of -10.64M.
Operating Cash Flow | -10.64M |
Capital Expenditures | n/a |
Free Cash Flow | -10.64M |
FCF Per Share | -1.01 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |